nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—UGT1A4—Tamoxifen—pancreatic cancer	0.374	0.458	CbGbCtD
Ezogabine—UGT1A9—Irinotecan—pancreatic cancer	0.116	0.142	CbGbCtD
Ezogabine—UGT1A1—Erlotinib—pancreatic cancer	0.105	0.128	CbGbCtD
Ezogabine—UGT1A1—Irinotecan—pancreatic cancer	0.0948	0.116	CbGbCtD
Ezogabine—CYP2A6—Tamoxifen—pancreatic cancer	0.0734	0.0898	CbGbCtD
Ezogabine—CYP2A6—Fluorouracil—pancreatic cancer	0.0541	0.0662	CbGbCtD
Ezogabine—Leukopenia—Sunitinib—pancreatic cancer	0.000491	0.00324	CcSEcCtD
Ezogabine—Coordination abnormal—Epirubicin—pancreatic cancer	0.000491	0.00324	CcSEcCtD
Ezogabine—Liver function test abnormal—Docetaxel—pancreatic cancer	0.000479	0.00316	CcSEcCtD
Ezogabine—Dysarthria—Doxorubicin—pancreatic cancer	0.000471	0.00311	CcSEcCtD
Ezogabine—Paraesthesia—Tamoxifen—pancreatic cancer	0.000469	0.00309	CcSEcCtD
Ezogabine—Dyspnoea—Tamoxifen—pancreatic cancer	0.000466	0.00307	CcSEcCtD
Ezogabine—Dyspnoea—Erlotinib—pancreatic cancer	0.000461	0.00304	CcSEcCtD
Ezogabine—Dyspepsia—Tamoxifen—pancreatic cancer	0.00046	0.00303	CcSEcCtD
Ezogabine—Alopecia—Irinotecan—pancreatic cancer	0.000459	0.00302	CcSEcCtD
Ezogabine—Gait disturbance—Doxorubicin—pancreatic cancer	0.000457	0.00301	CcSEcCtD
Ezogabine—Dry mouth—Sunitinib—pancreatic cancer	0.000457	0.00301	CcSEcCtD
Ezogabine—Dyspepsia—Erlotinib—pancreatic cancer	0.000455	0.003	CcSEcCtD
Ezogabine—Coordination abnormal—Doxorubicin—pancreatic cancer	0.000454	0.00299	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.000451	0.00298	CcSEcCtD
Ezogabine—Fatigue—Tamoxifen—pancreatic cancer	0.000451	0.00297	CcSEcCtD
Ezogabine—Dysphagia—Docetaxel—pancreatic cancer	0.000448	0.00296	CcSEcCtD
Ezogabine—Constipation—Tamoxifen—pancreatic cancer	0.000447	0.00295	CcSEcCtD
Ezogabine—Alopecia—Gemcitabine—pancreatic cancer	0.000447	0.00295	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.000446	0.00294	CcSEcCtD
Ezogabine—Fatigue—Erlotinib—pancreatic cancer	0.000446	0.00294	CcSEcCtD
Ezogabine—Infection—Sunitinib—pancreatic cancer	0.000445	0.00293	CcSEcCtD
Ezogabine—Constipation—Erlotinib—pancreatic cancer	0.000442	0.00292	CcSEcCtD
Ezogabine—Shock—Sunitinib—pancreatic cancer	0.00044	0.0029	CcSEcCtD
Ezogabine—Coma—Epirubicin—pancreatic cancer	0.00044	0.0029	CcSEcCtD
Ezogabine—Alopecia—Fluorouracil—pancreatic cancer	0.000439	0.0029	CcSEcCtD
Ezogabine—Nervous system disorder—Sunitinib—pancreatic cancer	0.000439	0.00289	CcSEcCtD
Ezogabine—Thrombocytopenia—Sunitinib—pancreatic cancer	0.000438	0.00289	CcSEcCtD
Ezogabine—Muscle spasms—Irinotecan—pancreatic cancer	0.000434	0.00286	CcSEcCtD
Ezogabine—Ill-defined disorder—Irinotecan—pancreatic cancer	0.000419	0.00276	CcSEcCtD
Ezogabine—Neutropenia—Docetaxel—pancreatic cancer	0.000419	0.00276	CcSEcCtD
Ezogabine—Ill-defined disorder—Gemcitabine—pancreatic cancer	0.000408	0.00269	CcSEcCtD
Ezogabine—Weight increased—Docetaxel—pancreatic cancer	0.000408	0.00269	CcSEcCtD
Ezogabine—Vision blurred—Fluorouracil—pancreatic cancer	0.000408	0.00269	CcSEcCtD
Ezogabine—Malaise—Irinotecan—pancreatic cancer	0.000407	0.00269	CcSEcCtD
Ezogabine—Coma—Doxorubicin—pancreatic cancer	0.000407	0.00269	CcSEcCtD
Ezogabine—Vertigo—Irinotecan—pancreatic cancer	0.000406	0.00268	CcSEcCtD
Ezogabine—Syncope—Irinotecan—pancreatic cancer	0.000405	0.00267	CcSEcCtD
Ezogabine—Leukopenia—Irinotecan—pancreatic cancer	0.000404	0.00267	CcSEcCtD
Ezogabine—Paraesthesia—Sunitinib—pancreatic cancer	0.000402	0.00265	CcSEcCtD
Ezogabine—Infestation—Docetaxel—pancreatic cancer	0.0004	0.00264	CcSEcCtD
Ezogabine—Infestation NOS—Docetaxel—pancreatic cancer	0.0004	0.00264	CcSEcCtD
Ezogabine—Dyspnoea—Sunitinib—pancreatic cancer	0.000399	0.00263	CcSEcCtD
Ezogabine—Loss of consciousness—Irinotecan—pancreatic cancer	0.000397	0.00262	CcSEcCtD
Ezogabine—Malaise—Gemcitabine—pancreatic cancer	0.000397	0.00262	CcSEcCtD
Ezogabine—Dyspepsia—Sunitinib—pancreatic cancer	0.000394	0.0026	CcSEcCtD
Ezogabine—Leukopenia—Gemcitabine—pancreatic cancer	0.000394	0.0026	CcSEcCtD
Ezogabine—Leukopenia—Fluorouracil—pancreatic cancer	0.000387	0.00255	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.000386	0.00255	CcSEcCtD
Ezogabine—Fatigue—Sunitinib—pancreatic cancer	0.000386	0.00255	CcSEcCtD
Ezogabine—Constipation—Sunitinib—pancreatic cancer	0.000383	0.00252	CcSEcCtD
Ezogabine—Discomfort—Irinotecan—pancreatic cancer	0.00038	0.00251	CcSEcCtD
Ezogabine—Hepatobiliary disease—Docetaxel—pancreatic cancer	0.000378	0.00249	CcSEcCtD
Ezogabine—Asthenia—Tamoxifen—pancreatic cancer	0.000375	0.00247	CcSEcCtD
Ezogabine—Increased appetite—Epirubicin—pancreatic cancer	0.000372	0.00246	CcSEcCtD
Ezogabine—Confusional state—Irinotecan—pancreatic cancer	0.000372	0.00245	CcSEcCtD
Ezogabine—Asthenia—Erlotinib—pancreatic cancer	0.000371	0.00245	CcSEcCtD
Ezogabine—Discomfort—Gemcitabine—pancreatic cancer	0.00037	0.00244	CcSEcCtD
Ezogabine—Infection—Irinotecan—pancreatic cancer	0.000366	0.00242	CcSEcCtD
Ezogabine—Discomfort—Fluorouracil—pancreatic cancer	0.000364	0.0024	CcSEcCtD
Ezogabine—Shock—Irinotecan—pancreatic cancer	0.000363	0.00239	CcSEcCtD
Ezogabine—Nervous system disorder—Irinotecan—pancreatic cancer	0.000362	0.00238	CcSEcCtD
Ezogabine—Thrombocytopenia—Irinotecan—pancreatic cancer	0.000361	0.00238	CcSEcCtD
Ezogabine—Infection—Gemcitabine—pancreatic cancer	0.000357	0.00235	CcSEcCtD
Ezogabine—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000356	0.00235	CcSEcCtD
Ezogabine—Confusional state—Fluorouracil—pancreatic cancer	0.000356	0.00235	CcSEcCtD
Ezogabine—Urinary tract disorder—Docetaxel—pancreatic cancer	0.000354	0.00234	CcSEcCtD
Ezogabine—Oedema peripheral—Docetaxel—pancreatic cancer	0.000353	0.00233	CcSEcCtD
Ezogabine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000352	0.00232	CcSEcCtD
Ezogabine—Urethral disorder—Docetaxel—pancreatic cancer	0.000352	0.00232	CcSEcCtD
Ezogabine—Thrombocytopenia—Gemcitabine—pancreatic cancer	0.000352	0.00232	CcSEcCtD
Ezogabine—Infection—Fluorouracil—pancreatic cancer	0.000351	0.00231	CcSEcCtD
Ezogabine—Diplopia—Epirubicin—pancreatic cancer	0.00035	0.00231	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—pancreatic cancer	0.00035	0.00231	CcSEcCtD
Ezogabine—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000347	0.00229	CcSEcCtD
Ezogabine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000346	0.00228	CcSEcCtD
Ezogabine—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000346	0.00228	CcSEcCtD
Ezogabine—Visual impairment—Docetaxel—pancreatic cancer	0.000346	0.00228	CcSEcCtD
Ezogabine—Dizziness—Tamoxifen—pancreatic cancer	0.000346	0.00228	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—pancreatic cancer	0.000345	0.00227	CcSEcCtD
Ezogabine—Dizziness—Erlotinib—pancreatic cancer	0.000342	0.00225	CcSEcCtD
Ezogabine—Eye disorder—Docetaxel—pancreatic cancer	0.000335	0.00221	CcSEcCtD
Ezogabine—Paraesthesia—Irinotecan—pancreatic cancer	0.000331	0.00218	CcSEcCtD
Ezogabine—Rash—Tamoxifen—pancreatic cancer	0.00033	0.00217	CcSEcCtD
Ezogabine—Dermatitis—Tamoxifen—pancreatic cancer	0.000329	0.00217	CcSEcCtD
Ezogabine—Dyspnoea—Irinotecan—pancreatic cancer	0.000329	0.00217	CcSEcCtD
Ezogabine—Somnolence—Irinotecan—pancreatic cancer	0.000328	0.00216	CcSEcCtD
Ezogabine—Rash—Erlotinib—pancreatic cancer	0.000326	0.00215	CcSEcCtD
Ezogabine—Dermatitis—Erlotinib—pancreatic cancer	0.000326	0.00215	CcSEcCtD
Ezogabine—Dyspepsia—Irinotecan—pancreatic cancer	0.000325	0.00214	CcSEcCtD
Ezogabine—Osteoarthritis—Doxorubicin—pancreatic cancer	0.000324	0.00213	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—pancreatic cancer	0.000324	0.00213	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000323	0.00213	CcSEcCtD
Ezogabine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000323	0.00213	CcSEcCtD
Ezogabine—Asthenia—Sunitinib—pancreatic cancer	0.000321	0.00212	CcSEcCtD
Ezogabine—Dyspnoea—Gemcitabine—pancreatic cancer	0.00032	0.00211	CcSEcCtD
Ezogabine—Somnolence—Gemcitabine—pancreatic cancer	0.000319	0.00211	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000318	0.0021	CcSEcCtD
Ezogabine—Fatigue—Irinotecan—pancreatic cancer	0.000318	0.0021	CcSEcCtD
Ezogabine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000317	0.00209	CcSEcCtD
Ezogabine—Alopecia—Docetaxel—pancreatic cancer	0.000317	0.00209	CcSEcCtD
Ezogabine—Constipation—Irinotecan—pancreatic cancer	0.000315	0.00208	CcSEcCtD
Ezogabine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000315	0.00208	CcSEcCtD
Ezogabine—Mental disorder—Docetaxel—pancreatic cancer	0.000314	0.00207	CcSEcCtD
Ezogabine—Somnolence—Fluorouracil—pancreatic cancer	0.000314	0.00207	CcSEcCtD
Ezogabine—Malnutrition—Docetaxel—pancreatic cancer	0.000312	0.00206	CcSEcCtD
Ezogabine—Dyspepsia—Fluorouracil—pancreatic cancer	0.000311	0.00205	CcSEcCtD
Ezogabine—Nausea—Tamoxifen—pancreatic cancer	0.00031	0.00205	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.00031	0.00204	CcSEcCtD
Ezogabine—Fatigue—Gemcitabine—pancreatic cancer	0.00031	0.00204	CcSEcCtD
Ezogabine—Constipation—Gemcitabine—pancreatic cancer	0.000307	0.00203	CcSEcCtD
Ezogabine—Nausea—Erlotinib—pancreatic cancer	0.000307	0.00203	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000305	0.00201	CcSEcCtD
Ezogabine—Feeling abnormal—Irinotecan—pancreatic cancer	0.000304	0.002	CcSEcCtD
Ezogabine—Influenza—Epirubicin—pancreatic cancer	0.000302	0.00199	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—pancreatic cancer	0.000302	0.00199	CcSEcCtD
Ezogabine—Muscle spasms—Docetaxel—pancreatic cancer	0.0003	0.00198	CcSEcCtD
Ezogabine—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000299	0.00197	CcSEcCtD
Ezogabine—Dizziness—Sunitinib—pancreatic cancer	0.000296	0.00195	CcSEcCtD
Ezogabine—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000296	0.00195	CcSEcCtD
Ezogabine—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000291	0.00192	CcSEcCtD
Ezogabine—Dysuria—Epirubicin—pancreatic cancer	0.000283	0.00186	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—pancreatic cancer	0.000283	0.00186	CcSEcCtD
Ezogabine—Rash—Sunitinib—pancreatic cancer	0.000282	0.00186	CcSEcCtD
Ezogabine—Dermatitis—Sunitinib—pancreatic cancer	0.000282	0.00186	CcSEcCtD
Ezogabine—Syncope—Docetaxel—pancreatic cancer	0.00028	0.00185	CcSEcCtD
Ezogabine—Dysphagia—Doxorubicin—pancreatic cancer	0.00028	0.00184	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—pancreatic cancer	0.00028	0.00184	CcSEcCtD
Ezogabine—Leukopenia—Docetaxel—pancreatic cancer	0.00028	0.00184	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—ACVR1B—pancreatic cancer	0.000277	0.00889	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ACVR1B—pancreatic cancer	0.000277	0.00889	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NR5A2—pancreatic cancer	0.000277	0.00889	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—TGFA—pancreatic cancer	0.000275	0.00886	CbGpPWpGaD
Ezogabine—Weight increased—Epirubicin—pancreatic cancer	0.000275	0.00181	CcSEcCtD
Ezogabine—Loss of consciousness—Docetaxel—pancreatic cancer	0.000275	0.00181	CcSEcCtD
Ezogabine—Infestation—Epirubicin—pancreatic cancer	0.00027	0.00178	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—pancreatic cancer	0.00027	0.00178	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—SLC2A2—pancreatic cancer	0.00027	0.00867	CbGpPWpGaD
Ezogabine—Nausea—Sunitinib—pancreatic cancer	0.000266	0.00175	CcSEcCtD
Ezogabine—Asthenia—Irinotecan—pancreatic cancer	0.000265	0.00174	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—pancreatic cancer	0.000262	0.00173	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—pancreatic cancer	0.000262	0.00173	CcSEcCtD
Ezogabine—Dry mouth—Docetaxel—pancreatic cancer	0.00026	0.00171	CcSEcCtD
Ezogabine—Asthenia—Gemcitabine—pancreatic cancer	0.000258	0.0017	CcSEcCtD
Ezogabine—Haematuria—Epirubicin—pancreatic cancer	0.000257	0.00169	CcSEcCtD
Ezogabine—Confusional state—Docetaxel—pancreatic cancer	0.000257	0.00169	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000255	0.00168	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—pancreatic cancer	0.000255	0.00168	CcSEcCtD
Ezogabine—Infection—Docetaxel—pancreatic cancer	0.000253	0.00167	CcSEcCtD
Ezogabine—Shock—Docetaxel—pancreatic cancer	0.000251	0.00165	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—PDX1—pancreatic cancer	0.00025	0.00804	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PDX1—pancreatic cancer	0.00025	0.00804	CbGpPWpGaD
Ezogabine—Nervous system disorder—Docetaxel—pancreatic cancer	0.00025	0.00165	CcSEcCtD
Ezogabine—Thrombocytopenia—Docetaxel—pancreatic cancer	0.00025	0.00165	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—pancreatic cancer	0.000249	0.00164	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—pancreatic cancer	0.000249	0.00164	CcSEcCtD
Ezogabine—Dizziness—Irinotecan—pancreatic cancer	0.000244	0.00161	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—NFE2L2—pancreatic cancer	0.00024	0.00772	CbGpPWpGaD
Ezogabine—Urinary tract disorder—Epirubicin—pancreatic cancer	0.000239	0.00158	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—pancreatic cancer	0.000238	0.00157	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—pancreatic cancer	0.000238	0.00157	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—pancreatic cancer	0.000237	0.00156	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000236	0.00156	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TYMS—pancreatic cancer	0.000235	0.00757	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—pancreatic cancer	0.000234	0.00753	CbGpPWpGaD
Ezogabine—Dizziness—Fluorouracil—pancreatic cancer	0.000234	0.00154	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—pancreatic cancer	0.000233	0.00154	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	0.000233	0.00749	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	0.000233	0.00749	CbGpPWpGaD
Ezogabine—Rash—Irinotecan—pancreatic cancer	0.000233	0.00153	CcSEcCtD
Ezogabine—Dermatitis—Irinotecan—pancreatic cancer	0.000232	0.00153	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—TGFA—pancreatic cancer	0.000229	0.00736	CbGpPWpGaD
Ezogabine—Paraesthesia—Docetaxel—pancreatic cancer	0.000229	0.00151	CcSEcCtD
Ezogabine—Dyspnoea—Docetaxel—pancreatic cancer	0.000227	0.0015	CcSEcCtD
Ezogabine—Somnolence—Docetaxel—pancreatic cancer	0.000227	0.00149	CcSEcCtD
Ezogabine—Rash—Gemcitabine—pancreatic cancer	0.000226	0.00149	CcSEcCtD
Ezogabine—Dermatitis—Gemcitabine—pancreatic cancer	0.000226	0.00149	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—pancreatic cancer	0.000226	0.00149	CcSEcCtD
Ezogabine—Dyspepsia—Docetaxel—pancreatic cancer	0.000224	0.00148	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—SLC2A2—pancreatic cancer	0.000224	0.0072	CbGpPWpGaD
Ezogabine—Rash—Fluorouracil—pancreatic cancer	0.000223	0.00147	CcSEcCtD
Ezogabine—Dermatitis—Fluorouracil—pancreatic cancer	0.000222	0.00147	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.000221	0.00146	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000221	0.00145	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.00022	0.00145	CcSEcCtD
Ezogabine—Fatigue—Docetaxel—pancreatic cancer	0.00022	0.00145	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—pancreatic cancer	0.000219	0.00145	CcSEcCtD
Ezogabine—Nausea—Irinotecan—pancreatic cancer	0.000219	0.00144	CcSEcCtD
Ezogabine—Constipation—Docetaxel—pancreatic cancer	0.000218	0.00144	CcSEcCtD
Ezogabine—Visual impairment—Doxorubicin—pancreatic cancer	0.000216	0.00142	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—pancreatic cancer	0.000214	0.00141	CcSEcCtD
Ezogabine—Nausea—Gemcitabine—pancreatic cancer	0.000213	0.00141	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—pancreatic cancer	0.000212	0.0014	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—pancreatic cancer	0.000211	0.00139	CcSEcCtD
Ezogabine—Feeling abnormal—Docetaxel—pancreatic cancer	0.00021	0.00139	CcSEcCtD
Ezogabine—Nausea—Fluorouracil—pancreatic cancer	0.00021	0.00138	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—pancreatic cancer	0.000209	0.00138	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—HSPA1A—pancreatic cancer	0.000207	0.00666	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NRP1—pancreatic cancer	0.000204	0.00656	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NRP1—pancreatic cancer	0.000204	0.00656	CbGpPWpGaD
Ezogabine—Muscle spasms—Epirubicin—pancreatic cancer	0.000203	0.00134	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—pancreatic cancer	0.000199	0.00131	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—pancreatic cancer	0.000198	0.0013	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—pancreatic cancer	0.000196	0.00129	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000195	0.00129	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—pancreatic cancer	0.000195	0.00129	CcSEcCtD
Ezogabine—Malaise—Epirubicin—pancreatic cancer	0.00019	0.00125	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—pancreatic cancer	0.000189	0.00125	CcSEcCtD
Ezogabine—Syncope—Epirubicin—pancreatic cancer	0.000189	0.00125	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—pancreatic cancer	0.000189	0.00124	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—pancreatic cancer	0.000187	0.00124	CcSEcCtD
Ezogabine—UGT1A9—PPAR Alpha Pathway—CCND1—pancreatic cancer	0.000186	0.00598	CbGpPWpGaD
Ezogabine—Loss of consciousness—Epirubicin—pancreatic cancer	0.000185	0.00122	CcSEcCtD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—pancreatic cancer	0.000184	0.00593	CbGpPWpGaD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	0.000184	0.00591	CbGpPWpGaD
Ezogabine—Vision blurred—Doxorubicin—pancreatic cancer	0.000184	0.00121	CcSEcCtD
Ezogabine—Asthenia—Docetaxel—pancreatic cancer	0.000183	0.00121	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000181	0.00119	CcSEcCtD
Ezogabine—Anxiety—Epirubicin—pancreatic cancer	0.000179	0.00118	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—pancreatic cancer	0.000177	0.00117	CcSEcCtD
Ezogabine—Malaise—Doxorubicin—pancreatic cancer	0.000176	0.00116	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—pancreatic cancer	0.000175	0.00116	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—pancreatic cancer	0.000175	0.00115	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—pancreatic cancer	0.000175	0.00115	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—pancreatic cancer	0.000174	0.00115	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—pancreatic cancer	0.000173	0.00114	CcSEcCtD
Ezogabine—UGT1A3—NRF2 pathway—HSPA1A—pancreatic cancer	0.000172	0.00554	CbGpPWpGaD
Ezogabine—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000171	0.00113	CcSEcCtD
Ezogabine—Infection—Epirubicin—pancreatic cancer	0.000171	0.00113	CcSEcCtD
Ezogabine—Shock—Epirubicin—pancreatic cancer	0.000169	0.00112	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000169	0.00111	CcSEcCtD
Ezogabine—Dizziness—Docetaxel—pancreatic cancer	0.000169	0.00111	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—pancreatic cancer	0.000168	0.00111	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000166	0.0011	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—NFE2L2—pancreatic cancer	0.000166	0.00533	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—NFE2L2—pancreatic cancer	0.000166	0.00533	CbGpPWpGaD
Ezogabine—Anxiety—Doxorubicin—pancreatic cancer	0.000165	0.00109	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	0.000164	0.00528	CbGpPWpGaD
Ezogabine—Discomfort—Doxorubicin—pancreatic cancer	0.000164	0.00108	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—pancreatic cancer	0.000162	0.00107	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	0.000161	0.00518	CbGpPWpGaD
Ezogabine—Rash—Docetaxel—pancreatic cancer	0.000161	0.00106	CcSEcCtD
Ezogabine—Dermatitis—Docetaxel—pancreatic cancer	0.000161	0.00106	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—pancreatic cancer	0.00016	0.00106	CcSEcCtD
Ezogabine—KCNQ3—L1CAM interactions—SRC—pancreatic cancer	0.000158	0.00509	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—SRC—pancreatic cancer	0.000158	0.00509	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFA—pancreatic cancer	0.000158	0.00509	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFA—pancreatic cancer	0.000158	0.00509	CbGpPWpGaD
Ezogabine—Infection—Doxorubicin—pancreatic cancer	0.000158	0.00104	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—SLC2A2—pancreatic cancer	0.000158	0.00507	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—SLC2A2—pancreatic cancer	0.000158	0.00507	CbGpPWpGaD
Ezogabine—Shock—Doxorubicin—pancreatic cancer	0.000157	0.00103	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000156	0.00103	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—pancreatic cancer	0.000156	0.00103	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—SLC2A2—pancreatic cancer	0.000155	0.00498	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC2A2—pancreatic cancer	0.000155	0.00498	CbGpPWpGaD
Ezogabine—Paraesthesia—Epirubicin—pancreatic cancer	0.000154	0.00102	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000154	0.00101	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	0.000153	0.00493	CbGpPWpGaD
Ezogabine—Dyspnoea—Epirubicin—pancreatic cancer	0.000153	0.00101	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—pancreatic cancer	0.000153	0.00101	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	0.000153	0.00491	CbGpPWpGaD
Ezogabine—Nausea—Docetaxel—pancreatic cancer	0.000151	0.000998	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—pancreatic cancer	0.000151	0.000998	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—IAPP—pancreatic cancer	0.00015	0.00481	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IAPP—pancreatic cancer	0.00015	0.00481	CbGpPWpGaD
Ezogabine—UGT1A9—PPAR Alpha Pathway—MYC—pancreatic cancer	0.000149	0.0048	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000148	0.000979	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—pancreatic cancer	0.000148	0.000977	CcSEcCtD
Ezogabine—Constipation—Epirubicin—pancreatic cancer	0.000147	0.00097	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000143	0.000942	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000142	0.000935	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—pancreatic cancer	0.000142	0.000934	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—pancreatic cancer	0.000141	0.000933	CcSEcCtD
Ezogabine—Dyspepsia—Doxorubicin—pancreatic cancer	0.00014	0.000923	CcSEcCtD
Ezogabine—KCNQ3—L1CAM interactions—EGFR—pancreatic cancer	0.000139	0.00446	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—EGFR—pancreatic cancer	0.000139	0.00446	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000137	0.000906	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—pancreatic cancer	0.000137	0.000904	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	0.000137	0.00439	CbGpPWpGaD
Ezogabine—Constipation—Doxorubicin—pancreatic cancer	0.000136	0.000897	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	0.000134	0.00431	CbGpPWpGaD
Ezogabine—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000131	0.000864	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—NFE2L2—pancreatic cancer	0.000128	0.00411	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	0.000128	0.0041	CbGpPWpGaD
Ezogabine—Asthenia—Epirubicin—pancreatic cancer	0.000123	0.000813	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—TGFA—pancreatic cancer	0.000122	0.00392	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SLC2A2—pancreatic cancer	0.000119	0.00384	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—HSPA1A—pancreatic cancer	0.000119	0.00383	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—HSPA1A—pancreatic cancer	0.000119	0.00383	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PRSS1—pancreatic cancer	0.000117	0.00376	CbGpPWpGaD
Ezogabine—Asthenia—Doxorubicin—pancreatic cancer	0.000114	0.000753	CcSEcCtD
Ezogabine—Dizziness—Epirubicin—pancreatic cancer	0.000114	0.00075	CcSEcCtD
Ezogabine—Rash—Epirubicin—pancreatic cancer	0.000108	0.000715	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—pancreatic cancer	0.000108	0.000714	CcSEcCtD
Ezogabine—KCNQ3—Axon guidance—KDR—pancreatic cancer	0.000106	0.0034	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—KDR—pancreatic cancer	0.000106	0.0034	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	0.000106	0.00339	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	0.000106	0.00339	CbGpPWpGaD
Ezogabine—Dizziness—Doxorubicin—pancreatic cancer	0.000105	0.000694	CcSEcCtD
Ezogabine—KCNQ3—Axon guidance—MET—pancreatic cancer	0.000104	0.00333	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MET—pancreatic cancer	0.000104	0.00333	CbGpPWpGaD
Ezogabine—Nausea—Epirubicin—pancreatic cancer	0.000102	0.000673	CcSEcCtD
Ezogabine—NAT2—Metabolism—ARG2—pancreatic cancer	0.000101	0.00326	CbGpPWpGaD
Ezogabine—Rash—Doxorubicin—pancreatic cancer	0.0001	0.000661	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—pancreatic cancer	0.0001	0.000661	CcSEcCtD
Ezogabine—KCNQ2—Developmental Biology—SMAD4—pancreatic cancer	9.64e-05	0.0031	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—SMAD4—pancreatic cancer	9.64e-05	0.0031	CbGpPWpGaD
Ezogabine—Nausea—Doxorubicin—pancreatic cancer	9.45e-05	0.000623	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	9.44e-05	0.00303	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	9.44e-05	0.00303	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HES1—pancreatic cancer	9.42e-05	0.00303	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HES1—pancreatic cancer	9.42e-05	0.00303	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	9.25e-05	0.00297	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	9.25e-05	0.00297	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—HSPA1A—pancreatic cancer	9.17e-05	0.00295	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TYMP—pancreatic cancer	8.87e-05	0.00285	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	8.81e-05	0.00283	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	8.81e-05	0.00283	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—HRAS—pancreatic cancer	8.79e-05	0.00283	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—HRAS—pancreatic cancer	8.79e-05	0.00283	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP2—pancreatic cancer	8.63e-05	0.00278	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP2—pancreatic cancer	8.63e-05	0.00278	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—PPARG—pancreatic cancer	8.26e-05	0.00266	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—pancreatic cancer	8.08e-05	0.0026	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—pancreatic cancer	7.81e-05	0.00251	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KDR—pancreatic cancer	7.55e-05	0.00243	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KDR—pancreatic cancer	7.55e-05	0.00243	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MET—pancreatic cancer	7.39e-05	0.00237	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MET—pancreatic cancer	7.39e-05	0.00237	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GLP1R—pancreatic cancer	7.15e-05	0.0023	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NOTCH1—pancreatic cancer	7.11e-05	0.00229	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NOTCH1—pancreatic cancer	7.11e-05	0.00229	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PRSS1—pancreatic cancer	7.09e-05	0.00228	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—DPYD—pancreatic cancer	7.03e-05	0.00226	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PPARG—pancreatic cancer	6.71e-05	0.00216	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PPARG—pancreatic cancer	6.71e-05	0.00216	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SLC2A2—pancreatic cancer	6.67e-05	0.00215	CbGpPWpGaD
Ezogabine—UGT1A4—NRF2 pathway—TGFB1—pancreatic cancer	6.52e-05	0.0021	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP9—pancreatic cancer	6.49e-05	0.00209	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—pancreatic cancer	6.49e-05	0.00209	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP2—pancreatic cancer	6.16e-05	0.00198	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP2—pancreatic cancer	6.16e-05	0.00198	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ARG2—pancreatic cancer	6.15e-05	0.00198	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—SRC—pancreatic cancer	5.98e-05	0.00192	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—SRC—pancreatic cancer	5.98e-05	0.00192	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PRSS1—pancreatic cancer	5.89e-05	0.00189	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—pancreatic cancer	5.83e-05	0.00187	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—pancreatic cancer	5.83e-05	0.00187	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—NRAS—pancreatic cancer	5.76e-05	0.00185	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—NRAS—pancreatic cancer	5.76e-05	0.00185	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—pancreatic cancer	5.57e-05	0.00179	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—TGFB1—pancreatic cancer	5.42e-05	0.00174	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TYMP—pancreatic cancer	5.37e-05	0.00173	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—EGFR—pancreatic cancer	5.24e-05	0.00169	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—EGFR—pancreatic cancer	5.24e-05	0.00169	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CD44—pancreatic cancer	5.17e-05	0.00166	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ARG2—pancreatic cancer	5.11e-05	0.00164	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GCG—pancreatic cancer	4.95e-05	0.00159	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—KRAS—pancreatic cancer	4.95e-05	0.00159	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—KRAS—pancreatic cancer	4.95e-05	0.00159	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—HRAS—pancreatic cancer	4.75e-05	0.00153	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—HRAS—pancreatic cancer	4.75e-05	0.00153	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CTNNB1—pancreatic cancer	4.72e-05	0.00152	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CTNNB1—pancreatic cancer	4.72e-05	0.00152	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—STK11—pancreatic cancer	4.66e-05	0.0015	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—pancreatic cancer	4.63e-05	0.00149	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—pancreatic cancer	4.63e-05	0.00149	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TYMP—pancreatic cancer	4.47e-05	0.00144	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GLP1R—pancreatic cancer	4.33e-05	0.00139	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—SRC—pancreatic cancer	4.27e-05	0.00137	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—SRC—pancreatic cancer	4.27e-05	0.00137	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—DPYD—pancreatic cancer	4.26e-05	0.00137	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—HRAS—pancreatic cancer	4.21e-05	0.00135	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—HRAS—pancreatic cancer	4.21e-05	0.00135	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—pancreatic cancer	4.16e-05	0.00134	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—pancreatic cancer	4.16e-05	0.00134	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—STAT3—pancreatic cancer	4.12e-05	0.00132	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—STAT3—pancreatic cancer	4.12e-05	0.00132	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NRAS—pancreatic cancer	4.11e-05	0.00132	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NRAS—pancreatic cancer	4.11e-05	0.00132	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PRSS1—pancreatic cancer	4.07e-05	0.00131	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PRSS1—pancreatic cancer	4.07e-05	0.00131	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SLC2A2—pancreatic cancer	4.04e-05	0.0013	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TYMS—pancreatic cancer	4.01e-05	0.00129	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TGFB1—pancreatic cancer	3.82e-05	0.00123	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TGFB1—pancreatic cancer	3.82e-05	0.00123	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—TGFB1—pancreatic cancer	3.75e-05	0.0012	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—TGFB1—pancreatic cancer	3.75e-05	0.0012	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EGFR—pancreatic cancer	3.74e-05	0.0012	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EGFR—pancreatic cancer	3.74e-05	0.0012	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GLP1R—pancreatic cancer	3.6e-05	0.00116	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—pancreatic cancer	3.56e-05	0.00115	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—pancreatic cancer	3.56e-05	0.00115	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—DPYD—pancreatic cancer	3.54e-05	0.00114	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KRAS—pancreatic cancer	3.53e-05	0.00114	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KRAS—pancreatic cancer	3.53e-05	0.00114	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ARG2—pancreatic cancer	3.53e-05	0.00114	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ARG2—pancreatic cancer	3.53e-05	0.00114	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SLC2A2—pancreatic cancer	3.36e-05	0.00108	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—APOE—pancreatic cancer	3.26e-05	0.00105	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PRSS1—pancreatic cancer	3.14e-05	0.00101	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CD44—pancreatic cancer	3.13e-05	0.00101	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TYMP—pancreatic cancer	3.09e-05	0.000992	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TYMP—pancreatic cancer	3.09e-05	0.000992	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HRAS—pancreatic cancer	3e-05	0.000966	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HRAS—pancreatic cancer	3e-05	0.000966	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GCG—pancreatic cancer	3e-05	0.000965	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CG—pancreatic cancer	2.94e-05	0.000946	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—TGFB1—pancreatic cancer	2.89e-05	0.000928	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPARG—pancreatic cancer	2.84e-05	0.000913	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—STK11—pancreatic cancer	2.82e-05	0.000908	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ARG2—pancreatic cancer	2.72e-05	0.000875	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—AKT1—pancreatic cancer	2.65e-05	0.000853	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—AKT1—pancreatic cancer	2.65e-05	0.000853	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CD44—pancreatic cancer	2.6e-05	0.000837	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CD—pancreatic cancer	2.59e-05	0.000831	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	2.55e-05	0.000819	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GCG—pancreatic cancer	2.5e-05	0.000802	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GLP1R—pancreatic cancer	2.49e-05	0.0008	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GLP1R—pancreatic cancer	2.49e-05	0.0008	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—DPYD—pancreatic cancer	2.45e-05	0.000787	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—DPYD—pancreatic cancer	2.45e-05	0.000787	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TYMS—pancreatic cancer	2.43e-05	0.000781	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TYMP—pancreatic cancer	2.38e-05	0.000765	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—STK11—pancreatic cancer	2.35e-05	0.000754	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC2A2—pancreatic cancer	2.32e-05	0.000747	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC2A2—pancreatic cancer	2.32e-05	0.000747	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	2.3e-05	0.000739	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CB—pancreatic cancer	2.25e-05	0.000725	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—pancreatic cancer	2.23e-05	0.000718	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	2.22e-05	0.000713	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	2.02e-05	0.00065	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TYMS—pancreatic cancer	2.02e-05	0.000649	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—APOE—pancreatic cancer	1.97e-05	0.000635	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTEN—pancreatic cancer	1.95e-05	0.000626	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GLP1R—pancreatic cancer	1.92e-05	0.000617	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—DPYD—pancreatic cancer	1.89e-05	0.000607	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CD44—pancreatic cancer	1.8e-05	0.000578	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CD44—pancreatic cancer	1.8e-05	0.000578	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC2A2—pancreatic cancer	1.79e-05	0.000576	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CG—pancreatic cancer	1.78e-05	0.000573	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.76e-05	0.000566	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.74e-05	0.000561	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GCG—pancreatic cancer	1.72e-05	0.000554	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GCG—pancreatic cancer	1.72e-05	0.000554	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPARG—pancreatic cancer	1.72e-05	0.000553	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—APOE—pancreatic cancer	1.64e-05	0.000528	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—STK11—pancreatic cancer	1.62e-05	0.000521	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—STK11—pancreatic cancer	1.62e-05	0.000521	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CD—pancreatic cancer	1.57e-05	0.000504	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	1.52e-05	0.000489	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CG—pancreatic cancer	1.48e-05	0.000476	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPARG—pancreatic cancer	1.43e-05	0.00046	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TYMS—pancreatic cancer	1.39e-05	0.000448	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TYMS—pancreatic cancer	1.39e-05	0.000448	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CD44—pancreatic cancer	1.39e-05	0.000446	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CA—pancreatic cancer	1.37e-05	0.000442	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CB—pancreatic cancer	1.37e-05	0.000439	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—pancreatic cancer	1.35e-05	0.000435	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GCG—pancreatic cancer	1.33e-05	0.000427	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CD—pancreatic cancer	1.3e-05	0.000419	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—STK11—pancreatic cancer	1.25e-05	0.000402	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTEN—pancreatic cancer	1.18e-05	0.000379	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CB—pancreatic cancer	1.13e-05	0.000365	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—APOE—pancreatic cancer	1.13e-05	0.000365	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—APOE—pancreatic cancer	1.13e-05	0.000365	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—pancreatic cancer	1.12e-05	0.000362	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKT1—pancreatic cancer	1.12e-05	0.000361	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TYMS—pancreatic cancer	1.07e-05	0.000346	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.07e-05	0.000345	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CG—pancreatic cancer	1.02e-05	0.000329	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CG—pancreatic cancer	1.02e-05	0.000329	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPARG—pancreatic cancer	9.88e-06	0.000318	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPARG—pancreatic cancer	9.88e-06	0.000318	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTEN—pancreatic cancer	9.81e-06	0.000315	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CD—pancreatic cancer	9e-06	0.000289	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CD—pancreatic cancer	9e-06	0.000289	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—APOE—pancreatic cancer	8.74e-06	0.000281	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CA—pancreatic cancer	8.32e-06	0.000268	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CG—pancreatic cancer	7.89e-06	0.000254	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CB—pancreatic cancer	7.84e-06	0.000252	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CB—pancreatic cancer	7.84e-06	0.000252	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—pancreatic cancer	7.77e-06	0.00025	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—pancreatic cancer	7.77e-06	0.00025	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPARG—pancreatic cancer	7.61e-06	0.000245	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CD—pancreatic cancer	6.94e-06	0.000223	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CA—pancreatic cancer	6.92e-06	0.000222	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKT1—pancreatic cancer	6.8e-06	0.000219	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTEN—pancreatic cancer	6.78e-06	0.000218	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTEN—pancreatic cancer	6.78e-06	0.000218	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CB—pancreatic cancer	6.05e-06	0.000194	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—pancreatic cancer	5.99e-06	0.000193	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKT1—pancreatic cancer	5.65e-06	0.000182	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTEN—pancreatic cancer	5.22e-06	0.000168	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	4.78e-06	0.000154	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CA—pancreatic cancer	4.78e-06	0.000154	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKT1—pancreatic cancer	3.91e-06	0.000126	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKT1—pancreatic cancer	3.91e-06	0.000126	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CA—pancreatic cancer	3.69e-06	0.000118	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKT1—pancreatic cancer	3.01e-06	9.68e-05	CbGpPWpGaD
